证券代码：603122 证券简称：合富中国 公告编号：临 2023-024 合富（中国）医疗科技股份有限公司 第二届监事会第六次会议决议公告 一、监事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届监事会 第六次会议于 2023 年 8 月 25 日上午在上海市虹漕路 456 号光启大楼 20 楼公司 董事会议室以现场方式召开，会议通知于 2023 年 8 月 14 日以电子邮件或书面 方式发出。会议由监事会主席陈晏女士主持，应到监事 3 人，实到监事 3 人。 会议的召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合法、 有效。 与会监事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、监事会会议审议情况 1、审议并通过了《关于公司 2023 年半年度报告及其摘要的议案》。 监事会认为：(1)公司 2023 年半年度报告及其摘要的编制和审议程序规范 合法，符合法律、法规、《公司章程》和公司内部管理制度的各项规定，内容真 实、准确、完整。 （2）公司 2023 年半年度报告及其摘要的内容和格式符合中国证监会和上 海证券交易所的各项规定，所包含的信息真实客观反映了公司 ...

合富（中国）医疗科技股份有限公司 第二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-023 1 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会 第六次会议于 2023 年 8 月 25 日在上海市虹漕路 456 号光启大楼 20 楼公司董事 会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合并书面表决方式召 开，会议通知于 2023 年 8 月 14 日以电子邮件或书面方式发出。本次会议由董 事长李惇先生主持，应到董事 7 人，实到董事 7 人，部分监事和高级管理人员 列席了会议。会议的召开符合法律法规、《公司法》及《公司章程》的规定，会 议决议合法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 1、审议并通过了《关于公司 2023 年半年度报告及其摘要的议案》。 具体内容详见公司同日在上海证券交易所网站（www.sse.c ...

1、关于 2023 年半年度募集资金的存放与实际使用情况专项报告的议案 合富（中国）医疗科技股份有限公司独立董事 关于公司第二届董事会第六次会议审议的相关事项 的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事规则》、《上市公司治理准则》、《合富（中国）医疗科技股份有限公司章程》 等有关规定，作为合富（中国）医疗科技股份有限公司（以下简称"公司"）的 独立董事，基于独立、客观判断的原则，我们对公司第二届董事会第六次会议审 议的相关事项发表独立意见如下： 经审慎查验，我们认为：公司 2023 年半年度募集资金存放与实际使用情况 符合法律法规和公司《募集资金管理制度》的规定，公司对募集资金进行了专户 存储和专项使用，不存在违规存放与使用募集资金的情形。同时，公司《2023 年 半年度募集资金的存放与实际使用情况专项报告》内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏，真实、客观地反映了公司 2023 年 半年度募集资金存放与使用情况。 合富（中国）医疗科技股份有限公司 独立董事：Stanley Yi Chang、雷永耀、周露露 2023 年 8 月 25 ...

特此公告。 合富（中国）医疗科技股份有限公司董事会 2023 年 1-7 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"） 之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公司定期报 告为准，敬请投资者注意投资风险。 公司 2023 年 1-7 月累计合并营业收入为人民币 64,462.77 万元，较去年同 期的合并营业收入减少 8.28%。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-022 合富（中国）医疗科技 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥267,190,714.93, representing a decrease of 13.25% compared to the same period last year[5] - Net profit attributable to shareholders was ¥9,222,339.66, down 39.09% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥9,797,345.31, a decrease of 37.00% compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a decline of 60.00% year-on-year[5] - Total operating revenue for Q1 2023 was ¥267,190,714.93, a decrease of 13.3% compared to ¥307,984,973.42 in Q1 2022[18] - Net profit for Q1 2023 was ¥9,111,154.02, a decline of 40.0% from ¥15,156,422.19 in Q1 2022[19] - Earnings per share for Q1 2023 were ¥0.02, compared to ¥0.05 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥113,986,510.74, indicating a significant cash outflow[5] - In Q1 2023, the company's cash inflow from operating activities was CNY 254,639,895.29, a decrease of 3.8% compared to CNY 264,643,033.90 in Q1 2022[22] - The net cash outflow from operating activities was CNY -113,986,510.74, worsening from CNY -67,054,010.90 in the same period last year[22] - The company's cash and cash equivalents decreased significantly, impacting liquidity ratios[19] - Cash inflow from financing activities totaled CNY 112,061,541.77, a decrease of 75% from CNY 448,199,884.89 in Q1 2022[23] - The net cash flow from financing activities was CNY 30,656,394.52, down from CNY 326,273,822.10 in the same quarter last year[23] - The company's cash and cash equivalents at the end of Q1 2023 were CNY 228,813,378.42, down from CNY 392,401,162.51 at the end of Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,507,131,250.60, down 3.33% from the end of the previous year[5] - Total assets as of Q1 2023 amounted to ¥1,507,131,250.60, a decrease from ¥1,559,065,109.86 in the previous year[16] - Total liabilities for Q1 2023 were ¥321,349,173.08, down from ¥380,491,021.65 in Q1 2022[16] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 241,769,403.33, down from RMB 326,855,769.22 as of December 31, 2022[14] - Accounts receivable increased to RMB 794,485,889.13 from RMB 746,897,311.83 year-over-year[14] - Total current assets decreased to RMB 1,354,330,563.06 from RMB 1,411,341,524.19[14] - Inventory as of March 31, 2023, was RMB 201,481,116.36, slightly down from RMB 204,822,603.19[14] Shareholder Information - Total number of common shareholders at the end of the reporting period was 40,762[11] - The largest shareholder, 合富（香港）控股有限公司, holds 218,937,885 shares, representing 55.00% of total shares[11] - The report indicates that there are no known relationships or concerted actions among the top shareholders[12] Operational Insights - The decline in net profit was primarily due to reduced service volume from end hospitals and decreased reagent procurement by customers[8] - The company's COVID-19 testing business had a minimal impact on the overall net profit, with only ¥760,000 in gross profit from related operations in the previous year[8] - The company expanded its sales, marketing, and R&D teams, leading to increased employee compensation and marketing expenses[8] - The company has not disclosed any new product or technology developments in the current report[13] - There are no significant mergers or acquisitions reported during the period[13] - The company has not provided specific future guidance or market expansion strategies in the current report[13] - Research and development expenses increased to ¥616,123.18 in Q1 2023 from ¥459,910.51 in Q1 2022, reflecting a focus on innovation[19] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,903,164.70 in Q1 2023 compared to -¥729,314.51 in Q1 2022[20] - The company is exploring market expansion strategies to recover from the decline in revenue and profit margins[19]

重要提示： 责任。 价值在线网站 https://www.ir-online.cn/ 会议召开方式：网络文字互动 投资者可于 2023 年 4 月 14 日（星期五）15:00 前将需要了解的情况和 有 关 问 题 预 先 通 过 电 子 邮 件 的 形 式 发 送 至 公 司 投 资 者 关 系 邮 箱 ： ir_cowealth@cowealth.com，也可通过访问网址 https://eseb.cn/13BAUw4QtsA 或使用微信扫描下方小程序码进行会前提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-015 合富（中国）医疗科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 一、说明会类型 合富（中国）医疗科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 22 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年经营成果、财务状况，公司计 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.28 billion, representing a year-on-year increase of 7.44% compared to ¥1.19 billion in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately ¥82.72 million, a 3.10% increase from ¥80.23 million in 2021[23]. - The total assets of the company reached approximately ¥1.56 billion, reflecting a year-on-year growth of 39.13% from ¥1.12 billion in 2021[23]. - The basic earnings per share for 2022 was ¥0.22, a decrease of 18.52% compared to ¥0.27 in 2021[24]. - The weighted average return on equity decreased to 7.56%, down 3.05 percentage points from 10.61% in 2021[24]. - The company reported a significant decline in cash flow from operating activities, primarily due to external environmental impacts and delayed payment arrangements from some clients[24]. - The company achieved a revenue of 1,279.67 million yuan in the reporting period, representing a year-on-year growth of 7.44%[38]. - The net profit attributable to shareholders of the listed company was 82.72 million yuan, an increase of 3.10% compared to the previous year[38]. - The gross profit margin for the main business was 20.13%, a decrease of 0.88 percentage points compared to the previous year[58]. - The company reported a significant increase in sales revenue from medical product circulation, which rose by 151.36% year-on-year[60]. Cash Flow and Dividends - The net cash flow from operating activities decreased significantly to approximately -¥30.37 million, down 533.09% from ¥7.01 million in 2021[23]. - The company plans to distribute cash dividends of RMB 1.50 per 10 shares, totaling approximately RMB 59.71 million, pending shareholder approval[147]. - The company declared a cash dividend of CNY 59,707,894.95, which represents 72.18% of the net profit attributable to ordinary shareholders in the consolidated financial statements[150]. - The company distributed a cash dividend of CNY 1.50 per 10 shares, with no stock dividends or capital increases[150]. Governance and Management - The company has a structured governance framework with a board of directors and supervisory committee in place[113]. - The management team consists of experts with extensive experience in the medical device industry, enhancing the company's ability to respond to market demands and maintain competitive advantages[52]. - The company has a clear strategy to avoid conflicts of interest with controlling shareholders, ensuring no reliance on them for procurement and sales functions[109]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 16.9066 million yuan[126]. - The company has a structured remuneration system based on the importance of roles, completion of business plans, and market average salary levels[125]. Strategic Initiatives and Market Position - The company aims to enhance its service capabilities by providing comprehensive value-added services to hospitals, including inventory management and professional training[36]. - The company is positioned to capitalize on the increasing demand for integrated services in the in vitro diagnostic product distribution and service industry[43]. - The company plans to enhance customer loyalty and service quality by providing tailored management software and supporting hospitals in achieving refined management goals[94]. - The company is committed to developing a cross-strait medical information sharing platform to optimize resource allocation and improve operational efficiency in hospitals[94]. - The company is considering strategic acquisitions to bolster its market position and diversify its product portfolio[115]. Risks and Challenges - The company faces risks from intensified market competition in the in vitro diagnostics industry, which may adversely affect its operations and profitability if it fails to enhance its product layout and service network[98]. - There is a risk associated with the lack of a controlling shareholder, which may lead to instability in governance and inefficiencies in major business decisions[98]. - The company has not yet been affected by centralized procurement policies at the national level, but future implementation could limit its supplier base and product categories, impacting its competitive advantage[99]. Corporate Social Responsibility - The company has not faced any environmental penalties and adheres to national environmental protection laws[157]. - The company promotes energy-saving and carbon reduction measures in daily operations, including the use of energy-efficient lighting and encouraging employees to use reusable utensils[162]. - Total external donations amounted to 1.8346 million CNY, with 480,000 CNY in cash donations and 1.3546 million CNY in material donations[163]. - The company supported hospitals by donating medical supplies including protective clothing, alcohol, testing reagents, and equipment to aid in pandemic response[163]. Legal and Compliance - The company has not reported any significant changes in competition or business operations that would affect its performance[109]. - The company has not faced any delisting risks or bankruptcy restructuring matters[187]. - The company has maintained a good integrity status during the reporting period, with no significant debts or court judgments outstanding[192]. - The company has been actively managing its legal and financial obligations, ensuring compliance with court rulings and payment schedules[192].

Financial Performance - The company's operating revenue for Q3 2022 was ¥332,003,570.72, representing a year-on-year increase of 10.71%[5] - The net profit attributable to shareholders was ¥17,741,560.57, a decrease of 4.46% compared to the same period last year[7] - The basic earnings per share for the period was ¥0.04, down 33.33% due to an increase in the weighted average number of shares following the company's initial public offering[11] - Total operating revenue for the first three quarters of 2022 reached ¥956,356,057.38, an increase of 6.3% compared to ¥899,100,448.02 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥54,232,528.04, slightly higher than ¥53,755,012.91 in the same period of 2021, indicating a growth of 0.9%[21] - The comprehensive income total for the first three quarters of 2022 was ¥68,110,129.18, compared to ¥53,508,966.31 in the same period of 2021, an increase of 27.3%[21] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,548,383,367.9, reflecting a 38.18% increase from the end of the previous year[6] - The total liabilities increased to ¥395,565,040.56 in Q3 2022 from ¥324,781,096.58 in Q3 2021, representing a growth of 21.8%[19] - The total equity attributable to shareholders reached ¥1,152,006,027.42, up from ¥795,832,606.71 in the previous year, marking an increase of 44.9%[19] Cash Flow - The cash flow from operating activities was not applicable for the current period, with a negative cash flow of ¥187,622,178.2 for the year-to-date[6] - In the first three quarters of 2022, the cash inflow from operating activities was approximately $795.74 million, a decrease of about 9.0% compared to $874.62 million in the same period of 2021[23] - The net cash flow from operating activities was negative at approximately -$187.62 million, worsening from -$63.12 million in the first three quarters of 2021[23] - The cash inflow from investment activities totaled approximately $3.37 million, an increase from $2.99 million in the same period of 2021[24] - The net cash flow from investment activities was negative at approximately -$52.77 million, compared to -$3.40 million in the first three quarters of 2021[24] - The cash inflow from financing activities was approximately $633.64 million, significantly higher than $254.92 million in the same period of 2021[24] - The net cash flow from financing activities was positive at approximately $287.60 million, a turnaround from -$86.27 million in the first three quarters of 2021[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,285[13] - The largest shareholder, 合富（香港）控股有限公司, holds 218,937,885 shares, representing 55.00% of total shares[13] - The company reported a total of 19,700,000 shares (4.95%) held by 招商局资本管理有限责任公司[13] Operational Challenges - The company experienced delays in customer payments due to recurring national pandemic issues, impacting cash flow and accounts receivable[11] - The company received government subsidies amounting to ¥1,100,000.00 during the year, which are closely related to its normal business operations[9] Inventory and Receivables - Accounts receivable increased to ¥812,752,306.14 from ¥545,653,297.06 year-over-year[16] - Inventory as of September 30, 2022, is ¥202,776,940.98, up from ¥178,858,307.89[17] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥2,269,736.91, indicating ongoing investment in innovation[20] Strategic Focus - The company plans to continue focusing on expanding its market presence and developing new technologies in the healthcare sector[1] - The company continues to focus on market expansion and new product development as part of its strategic initiatives[22]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥624.35 million, representing a 4.20% increase compared to ¥599.22 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥36.51 million, a 3.64% increase from ¥35.23 million in the previous year[18]. - The basic earnings per share for the first half of 2022 was ¥0.10, down 16.67% from ¥0.12 in the same period last year[19]. - The company achieved a revenue of ¥624,352,486.66, representing a year-on-year growth of 4.20%[44]. - The net profit attributable to shareholders was ¥36,512,739.53, reflecting a year-on-year increase of 3.64%[44]. - Total revenue for the first half of 2022 reached ¥624,352,486.66, an increase of 4.3% compared to ¥599,215,210.77 in the same period of 2021[135]. - Operating profit for the first half of 2022 was ¥51,503,126.45, slightly up from ¥50,114,985.21 in the first half of 2021[136]. Cash Flow and Assets - The net cash flow from operating activities was negative at approximately -¥88.09 million, compared to -¥47.67 million in the same period last year, indicating a significant decline[18]. - The total assets at the end of the reporting period were approximately ¥1.45 billion, a 29.30% increase from ¥1.12 billion at the end of the previous year[18]. - The company's cash and cash equivalents reached ¥258,578,459.28, accounting for 17.85% of total assets, a 76.38% increase from the previous year[50]. - Accounts receivable amounted to ¥709,949,272.85, representing 49.00% of total assets, with a year-on-year increase of 30.11%[51]. - The company's cash flow from operating activities was negative at -¥88,087,926.63, primarily due to delayed customer payments caused by the pandemic[48]. - The total cash and cash equivalents at the end of the first half of 2022 amounted to RMB 247,873,612.20, an increase from RMB 130,251,423.41 at the end of the first half of 2021[141]. Market and Industry Insights - The IVD industry in China reached a market size of 133.6 billion RMB in 2021, growing by 24.3% year-on-year, with expectations to exceed 300 billion RMB by 2027[27]. - The competition in the IVD reagent market is intensifying, with domestic companies holding a 50% market share in immunodiagnostics, while other segments are dominated by foreign firms[28]. - The company highlighted that the demand for IVD products is concentrated in densely populated and economically developed coastal regions, with a seasonal demand pattern observed[26]. Strategic Initiatives - The company is focusing on enhancing its comprehensive service capabilities to meet the increasing demands of end-users for logistics, maintenance, and value-added services[29]. - The company plans to leverage technological innovations and market expansion strategies to capture a larger share of the growing IVD market[27]. - The company has established a comprehensive integrated service system for medical institutions, focusing on centralized procurement and management of diagnostic reagents and consumables, which helps reduce costs for hospitals[34]. - The company has signed long-term contracts with over 1,000 suppliers, covering nearly 17,000 items of in vitro diagnostic reagents and consumables, enhancing its competitive advantage in the market[35]. Research and Development - Research and development expenses increased to ¥1,635,162.62, attributed to the establishment of a software development team[48]. - The company is actively developing proprietary hospital department management software to enhance operational efficiency for hospitals[41]. Legal and Compliance - The company reported a significant lawsuit involving a claim amounting to RMB 15,030,835 related to a service agreement dispute[99]. - The company has maintained a good integrity status during the reporting period, with no significant debts or court judgments unmet[102]. - The company strictly adhered to environmental protection laws and regulations, with no violations or administrative penalties reported during the reporting period[73]. Shareholder and Governance - The company held its annual shareholders' meeting on April 28, 2022, where 16 proposals were approved, including the annual report for 2021[65]. - The company did not propose any profit distribution or capital reserve transfer plan for the first half of 2022, with no dividends or stock bonuses declared[70]. - The company appointed a new deputy general manager and elected new directors during the first meeting of the second board of directors[68]. Financial Stability and Risks - The company faces risks from intensified market competition in the in vitro diagnostic industry, which could adversely affect its operations and profitability[60]. - The company has reported no changes in the audit opinion from the previous year, indicating stable financial oversight[98]. - The company has not undergone any bankruptcy restructuring during the reporting period, reflecting its financial stability[98].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 307,984,973.42, representing a year-on-year increase of 19.67%[5] - The net profit attributable to shareholders for the same period was CNY 15,142,001.71, reflecting a growth of 7.24% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 15,551,864.28, which is an increase of 21.05% year-on-year[5] - The company's net profit for Q1 2022 was CNY 15,156,422.19, an increase from CNY 14,119,885.02 in Q1 2021, representing a growth of approximately 7.35%[21] - Operating profit for Q1 2022 reached CNY 21,627,768.36, compared to CNY 17,276,332.23 in the same period last year, indicating a year-over-year increase of about 25.5%[21] - Total revenue from sales of goods and services amounted to CNY 262,830,985.28, up from CNY 239,863,277.49 in Q1 2021, reflecting an increase of approximately 9.4%[23] - The company reported a total comprehensive income of CNY 14,427,107.68 for Q1 2022, down from CNY 16,120,954.88 in the previous year[22] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -67,054,010.90, indicating a significant cash outflow[5] - The net cash flow from operating activities was negative at CNY -67,054,010.90, an improvement from CNY -129,587,750.26 in Q1 2021[24] - The company's cash and cash equivalents increased significantly to RMB 402,472,481.69 from RMB 146,602,627.28, marking a growth of 174%[15] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 392,401,162.51, significantly higher than CNY 102,574,182.93 at the end of Q1 2021[24] - Total assets at the end of the reporting period reached CNY 1,468,577,882.18, marking a 31.06% increase from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to RMB 1,468,577,882.18, up from RMB 1,120,547,775.27 at the end of 2021, representing a growth of approximately 31%[16] Shareholder Information - Equity attributable to shareholders increased by 47.01% to CNY 1,169,950,707.80, driven by new share issuance and net profit growth[6] - The equity attributable to shareholders increased to RMB 1,169,950,707.80 from RMB 795,832,606.71, reflecting a growth of approximately 47%[17] - The total number of ordinary shareholders at the end of the reporting period was 59,356[10] - The largest shareholder, 合富（香港）控股有限公司, held 55% of the shares, totaling 218,937,885 shares[10] Costs and Expenses - Total operating costs for Q1 2022 were RMB 280,874,945.36, up from RMB 238,994,711.41 in Q1 2021, reflecting a growth of approximately 17.5%[20] - The company’s total expenses for sales increased to CNY 15,534,252.85 in Q1 2022 from CNY 12,279,438.70 in Q1 2021, marking a rise of approximately 26.3%[21] - The financial expenses showed a significant decrease, with interest expenses at CNY 900,855.69 compared to CNY 945,929.04 in the previous year[21] Strategic Focus - The company is focusing on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[20] - There were no significant mergers or acquisitions reported during the quarter, with a focus on organic growth strategies[20] Return Metrics - The basic earnings per share for the quarter was CNY 0.05, unchanged from the previous year[5] - Basic and diluted earnings per share remained stable at CNY 0.05 for both Q1 2022 and Q1 2021[22] - The weighted average return on equity was 1.64%, an increase of 0.33 percentage points compared to the previous year[6]